Miach Orthopaedics Raises $20 Million in Series B Extension
Summary
The Major League Soccer Players Association (MLSPA), SV Health Investors and Aperture Venture Partners Join Existing Investors to Support Commercial Expansion and Clinical Activities for BEAR\xae ImplantWESTBOROUGH, Mass., April 2, 2024-- Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR\xae) Implant, today announced closing of a $20 million Series B extension financing round. The funds will support commercial expansion and clinical activities for the BEAR Implant, which has been used to treat nearly 3,000 patients with anterior cruciate ligament (ACL) tears. This financing will enable continued growth of our commercial organization in the U.S., as well as support clinical initiatives like the Bridge Registry to provide important data on real-world patient outcomes, said Patrick McBrayer, president and CEO, Miach Orthopaedics. We are excited to welcome the MLSPA, whose investment demonstrates the potential of the BEAR Implant to be a game changer for professional athletes, as well as SV Health Investors and Aperture Venture Partners. This Series B extension diversifies Miachs investor group and provides additional resources to further market growth in the U.S. toward the goal of establishing the BEAR Implant as a new standard of care for ACL tears.